G.M. ZAYNETDINOVA¹, R.F. KHAKIMOVA², G.A. SHAMSUTDINOVA¹, G.R. ZYAPBAROVA¹

¹Children Republican Clinical Hospital, 140 Orenburgskiy Trakt, Kazan, Russian Federation, 420064

²Кazan State Medical University, 49 Butlerov Str., Kazan, Russian Federation, 420012

Zaynetdinova Gulnara Mukaryamovna ― Head of the Department of Allergology, tel. +7-917-275-11-76, e-mail: gulnara-z@rambler.ru¹

Khakimova Rezeda Fidailovna ― D. Med. Sc., Professor of the Department of Clinical Immunology and Allergology, tel. +7-937-285-75-38, e-mail: khakimova@yandex.ru²

Shamsutdinova Galina Aleksandrovna ― doctor of the Department of Allergology, tel. +7-937-776-88-02, e-mail: galina2302@mail.ru¹

Zyapbarova Gulnara Ramilevna ― doctor of the Department of Allergology, tel. +7-965-597-75-78, e-mail: gulnara.ramilevna@inbox.ru¹

Anti-IgE therapy is pathogenetically justified and aimed at prevention of acute allergic inflammation. The article presents the experience of curing children with severe bronchial asthma with Omalizumab in addition to basic therapy. The clinical course of the disease during six months of observation was analyzed. The positive dynamics was shown, including the reliable decrease in the frequency of hospitalizations for acute asthma exacerbations and a possibility to reduce the basic doses of drugs without clinical compromise. It should be highlighted that the clinical improvement of the disease course directly correlated with the reliable results of pulmonary function tests. No side effects of Omalizumab were observed.

Key words: Bronchial Asthma, children, anti-IgE therapy, omalizumab.

REFERENCES

1. Global Initiative for Asthma. Workshop Report, 2014.
2. Sokolova L.V., Tsyplenkova S.E., Sorokina L.V., Mizernitskiy Yu.L. Experience of prolonged use of omalizumab in children with severe asthma. Zemskiy vrach, 2011, no. 5 (9), pp. 21-24 (in Russ.).
3. Kulichenko T.V. Omalizumab in children with asthma: indications for use. Pediatricheskaya farmakologiya, 2007, vol. 4, no. 6, pp. 51-55 (in Russ.).
4. Deschildre A., Marguet C., Salleron J., Pin I., Rittié JL., Derelle J. et al.  Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J, 2013, no. 42, pp. 1224-33.
5. Lanier B., Bridges T., Kulus M., Taylor A.F., Berhane I., Vidaurre C.F. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J. Allergy Clin Immunol, 2009, no. 124, pp. 1210-1216.